Stockreport

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

AC Immune SA  (ACIU) 
Last ac immune sa earnings: 11/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: acimmune.com/en/investors
PDF Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of th [Read more]